Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature

Xubo Gong; Lijuan Yan; Xibin Xiao; Qiusu Tang; Xiaoying Zhao

Secondary mixed phenotype acute leukemia following chemotherapy for diffuse large B-cell lymphoma: a case report and review of the literature

Int J Clin Exp Pathol. 2018 Jun 1;11(6):3104-3110. eCollection 2018.

Authors

Xubo Gong¹, Lijuan Yan², Xibin Xiao³, Qiusu Tang⁴, Xiaoying Zhao³

Affiliations

¹ Department of Clinical Laboratory, The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, China.
² Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, China.
³ Department of Hematology, The Second Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, China.
⁴ Department of Pathology, The First Affiliated Hospital, School of Medicine, Zhejiang University Hangzhou, China.

PMID: 31938438
PMCID: PMC6958080

Abstract

Therapy-related mixed phenotype acute leukemia (MPAL) following non-Hodgkin's lymphoma (NHL) is extremely rare. We present here the case of an elderly man, diagnosed with diffuse large B-cell lymphoma (DLBCL) through a tonsil biopsy. After treatment with seven cycles of CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) like regimen, the patient developed to MPAL (B/myeloid) with del(7)(q22), t(6;9)(p23;q34), DEK/NUP214 fusion, as well as EZH2 and TET2 mutations. The patient was successively treated with chemotherapy and allogenetic hematopoietic stem cell transplantation. Until recently he is still alive more than 23 months without relapse.

Keywords: CHOP; Diffuse large B-cell lymphoma; mixed phenotype acute leukemia.

Publication types

Case Reports